These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7690080)

  • 1. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter.
    Buchanan LV; Turcotte UM; Kabell GG; Gibson JK
    J Cardiovasc Pharmacol; 1993 Jul; 22(1):10-4. PubMed ID: 7690080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model.
    Buchanan LV; LeMay RJ; Walters RR; Hsu CY; Brunden MN; Gibson JK
    J Cardiovasc Electrophysiol; 1996 Feb; 7(2):113-9. PubMed ID: 8853021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents.
    Buchanan LV; Kabell G; Gibson JK
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):539-44. PubMed ID: 7596120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing.
    Stambler BS; Wood MA; Ellenbogen KA
    Am J Cardiol; 1996 May; 77(11):960-6. PubMed ID: 8644646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The study of inhibiting heart rate and rapidly terminating atrial flutter of ibutilide on canine].
    Sun JL; Li XY; Guo JH; Liu P; Zhang P; Yi Z
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Oct; 37(10):920-4. PubMed ID: 20137545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ibutilide on inhibiting heart rate and rapidly terminating atrial flutter in canine.
    Sun J; Li X; Guo J; Liu P; Zhang P
    Cell Biochem Biophys; 2011 Apr; 59(3):153-8. PubMed ID: 20972643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.
    Ellenbogen KA; Stambler BS; Wood MA; Sager PT; Wesley RC; Meissner MC; Zoble RG; Wakefield LK; Perry KT; Vanderlugt JT
    J Am Coll Cardiol; 1996 Jul; 28(1):130-6. PubMed ID: 8752805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of acute inducible atrial flutter in dogs by using an ibutilide-polymer-coated pacing electrode.
    Labhasetwar V; Strickberger SA; Underwood T; Davis J; Levy RJ
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):449-55. PubMed ID: 9514191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination.
    Tai CT; Chen SA; Feng AN; Yu WC; Chen YJ; Chang MS
    Circulation; 1998 May; 97(19):1935-45. PubMed ID: 9609087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability.
    Guo GB; Ellenbogen KA; Wood MA; Stambler BS
    J Am Coll Cardiol; 1996 Apr; 27(5):1083-9. PubMed ID: 8609325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.
    Cha Y; Wales A; Wolf P; Shahrokni S; Sawhney N; Feld GK
    J Cardiovasc Electrophysiol; 1996 Sep; 7(9):809-27. PubMed ID: 8884510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ibutilide for termination of atrial fibrillation and flutter.
    Ellenbogen KA; Clemo HF; Stambler BS; Wood MA; VanderLugt JT
    Am J Cardiol; 1996 Oct; 78(8A):42-5. PubMed ID: 8903275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.
    Stambler BS; Wood MA; Ellenbogen KA
    Circulation; 1997 Dec; 96(12):4298-306. PubMed ID: 9416896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation.
    Nair M; George LK; Koshy SK
    J Am Board Fam Med; 2011; 24(1):86-92. PubMed ID: 21209348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.
    Howard PA
    Ann Pharmacother; 1999 Jan; 33(1):38-47. PubMed ID: 9972384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation.
    Volgman AS; Carberry PA; Stambler B; Lewis WR; Dunn GH; Perry KT; Vanderlugt JT; Kowey PR
    J Am Coll Cardiol; 1998 May; 31(6):1414-9. PubMed ID: 9581743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiologic effects of a new class III antiarrhythmic agent, E-4031, on atrial flutter, atrial refractoriness, and conduction delay in a canine sterile pericarditis model.
    Shimizu A; Kaibara M; Centurion OA; Kapuku G; Hirata T; Fukatani M; Yano K; Hashiba K
    J Cardiovasc Pharmacol; 1993 Apr; 21(4):656-62. PubMed ID: 7681913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation.
    Foster RH; Wilde MI; Markham A
    Drugs; 1997 Aug; 54(2):312-30. PubMed ID: 9257085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-injection of magnesium sulfate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter.
    Steinwender C; Hönig S; Kypta A; Kammler J; Schmitt B; Leisch F; Hofmann R
    Int J Cardiol; 2010 Jun; 141(3):260-5. PubMed ID: 19136164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide.
    Stump GL; Wallace AA; Regan CP; Lynch JJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1362-7. PubMed ID: 16157659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.